Actively Recruiting
Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients With Type 1 Diabetes
Led by Yang Tao · Updated on 2026-04-20
80
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The blood glucose fluctuates greatly in T1DM patients, especially in the middle and late stages of the disease, and carbohydrate (CHO) is the main determinant of postprandial glucose response (PGR). Based on the previous investigation to understand how nutritional habits affect blood glucose control, we will conduct dietary intervention studies in T1DM patients to explore whether the adjustment of dietary pattern is beneficial to blood glucose control, and further explore the relevant mechanism through the detection of related metabolic indicators.
CONDITIONS
Official Title
Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients With Type 1 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to participate and sign informed consent
- Diagnosed with type 1 diabetes mellitus (ADA2024)
- Aged 18 to 70 years
- Dependent on exogenous insulin therapy with stable treatment plan for 2 months (type unchanged, dose adjustable)
- Body mass index (BMI) between 18 and 25 kg/m2
- HbA1c less than or equal to 11%
You will not qualify if you...
- In honeymoon phase of type 1 diabetes mellitus
- Pregnant or planning pregnancy
- Vegetarian or currently on weight loss diet
- Using oral hypoglycemic drugs like alpha-glucosidase inhibitors or DPP-IV inhibitors
- Used glucocorticoids within the past 30 days
- History of severe food allergy
- Experienced diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) within 6 months
- Have gastroparesis, inflammatory bowel disease, or similar complications
- Have large albuminuria or renal insufficiency
- Have uncontrolled hyperthyroidism or hypothyroidism
- History of heart disease, coronary heart disease, or arrhythmia
- Serious liver dysfunction (ALT or AST over 3 times normal limit)
- History of malignant tumors or tumors/surgeries affecting digestion and nutrient absorption
- Uncontrolled immune system diseases or infections
- Alcohol or drug abuse, mental disorders, or other conditions unsuitable for drug study
- Any disease interfering with participation or evaluation in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital, Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
T
Tao Yang, MD/PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here